Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
JCO Oncology Practice · 2026-10 · 22 (10) · 1701-1712
DOI: 10.1200/op-25-00646 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift JCO Oncology Practice, 2026-10. Verfasst von Amy H Huang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Connecticut School of Medicine, Farmington, CT. Hauptthemen laut MEDLINE: Antineoplastic Agents, Colorectal Neoplasms, ErbB Receptors, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Clonal evolution is a mechanism of treatment resistance against epidermal growth factor receptor inhibitors (EGFRi) in metastatic colorectal cancer (mCRC). When EGFRi is discontinued, EGFRi-resistant tumor subclones decay with time, allowing for EGFRi rechallenge at later time. We conducted a meta-analysis to investigate the efficacy of EGFRi rechallenge in mCRC. METHODS Clinical trials and observational studies investigating the efficacy of EGFRi rechallenge in mCRC were included from PubMed and Embase from inception to December 8, 2024. Hazard ratios (HRs) of overall survival (OS) and progression-free survival (PFS) were aggregated using Bayesian random-effects models. Objective response rates (ORRs) were aggregated using meta-random-effects models. RESULTS Twenty-nine studies were included. The pooled median PFS, median OS, and ORR were 3.83 months (95% CI, 3.25 to 4.50), 10.43 months (95% CI, 8.14 to 13.36), and 14.61% (95% CI, 8.70 to 23.51), respectively. EGFRi rechallenge was associated with significantly longer pooled PFS (HR, 0.54 [95% CI, 0.31 to 0.93]) and numerically longer pooled OS (HR, 0.71 [95% CI, 0.46 to 1.09]) than non-EGFRi systemic therapy. Patients without detectable RAS/RAF mutations by circulating tumor DNA (ctDNA) at the time of EGFRi rechallenge had significantly longer OS (HR, 0.43 [95% CI, 0.24 to 0.75]) and PFS (HR, 0.40 [95% CI, 0.26 to 0.62]) than those with ctDNA RAS/RAF mutations. Studies with EGFRi-free intervals ≥4 months before rechallenge (18.77%) had a numerically greater pooled ORR than those with EGFRi-free intervals
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Connecticut School of Medicine, Farmington, CT.
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
- Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
- Division of Hematology/Oncology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
- Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Irvine, CA.
ORCID-Profile: Amy H Huang, Chuan Angel Lu, Ibrahim Halil Sahin, Gentry T King, Rachael A Safyan, David B Zhen, Veena Shankaran, Andrew L Coveler, Jyoti Malhotra, Victoria E Forbes, E Gabriela Chiorean, Ronan W Hsieh
Zitieren
APA
Huang, A. H., Lee, G. Y., Lu, C. A., Sahin, I. H., King, G. T., Safyan, R. A., Cohen, S. A., Zhen, D. B., Shankaran, V., Harris, W. P., Coveler, A. L., Malhotra, J., Forbes, V. E., Gold, P. J., Chiorean, E. G., & Hsieh, R. W. (2026). Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. JCO Oncology Practice, 22(10), 1701-1712. https://doi.org/10.1200/op-25-00646
Vancouver
Huang AH, Lee GY, Lu CA, Sahin IH, King GT, Safyan RA, et al. Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. JCO Oncology Practice. 2026;22(10):1701-1712. doi:10.1200/op-25-00646
BibTeX
@article{Huang2026,
author = {Huang, Amy H and Lee, Gin Yi and Lu, Chuan Angel and Sahin, Ibrahim Halil and King, Gentry T and Safyan, Rachael A and Cohen, Stacey A and Zhen, David B and Shankaran, Veena and Harris, William P and Coveler, Andrew L and Malhotra, Jyoti and Forbes, Victoria E and Gold, Philip J and Chiorean, E Gabriela and Hsieh, Ronan W},
title = {Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis},
journal = {JCO Oncology Practice},
year = {2026},
volume = {22},
number = {10},
pages = {1701--1712},
doi = {10.1200/op-25-00646}
}
EUVIMED